• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Artificial Intelligence / Human Intelligence Workshop: 2025

Artificial Intelligence / Human Intelligence Workshop: 2025

by Elena Iemma | Dec 28, 2024 | Events, Featured

Tentative date: June 5 & 6, 2025 9:00am – 5:00pm (with receptions to follow!) 350 Eddy St. Providence, RI 02903 Save the Date The second Artificial Intelligence / Human Intelligence Workshop is tentatively planned for June 5 and 6th at the South Street...
Artificial Intelligence / Human Intelligence & Immunoinformatics Workshop ’24

Artificial Intelligence / Human Intelligence & Immunoinformatics Workshop ’24

by Elena Iemma | Mar 5, 2024 | Events

June 13 & 14, 2024 9:00am – 5:00pm (with receptions to follow!) 350 Eddy St. Providence, RI 02903 Registration is closed The Artificial Intelligence / Human Intelligence & Immunoinformatics Workshop will take place on June 13 and 14th at the South Street...
EpiVax CEO Speaks at the Hwasun International Vaccine and Immunotherapy Forum

EpiVax CEO Speaks at the Hwasun International Vaccine and Immunotherapy Forum

by Elena Iemma | Nov 20, 2023 | News

EpiVax CEO Annie De Groot was one of three plenary session speakers at a recent international forum on vaccines organized by Joon Rhee. Her topic was ‘Better, Safer, and Personalized Vaccines will Result from Human + Artificial Intelligence’. Other speakers...

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.